###### Strengths and limitations of this study

-   This study includes articles from different regions of the country which support the representativeness of the evidence obtained at the country level.

-   In addition to this, inclusion of more than 30 articles for both quantitative and qualitative synthesis was considered as the major strength of this study.

-   The variation in the study design used among the included studies and the inclusion of only observational studies were considered as the major drawback of this study.

Introduction {#s1}
============

Tuberculosis (TB) is an infectious disease caused by a bacteria called *Mycobacterium tuberculosis*. It is a preventable and curable disease mainly transmitted through air from person to person. Majorly, it affects the lungs, but it can also damage other organs in the body.[@R1] Common symptoms of active lung TB are cough with sputum and blood, chest pains, weakness, weight loss, fever and night sweats.[@R1]

TB is the ninth leading cause of death globally and the leading cause from a single infectious agent, ranking above HIV/AIDS. In 2016, it was responsible for an estimated 1.3 million and 374 000 TB deaths among HIV-negative and HIV-infected people, respectively.[@R3] It is also the number one cause of death among HIV-infected individuals with an estimated two-fifth deaths among HIV-infected individuals being due to TB.[@R1]

Ethiopia is among the countries where TB is highly prevalent. WHO prepared three lists of countries based on the burden of TB, TB/HIV co-infection and multidrug-resistant TB (MDR-TB). Accordingly, Ethiopia is among the 14 countries where there is high burden of TB, TB/HIV co-infection and MDR-TB. Even though the incidence of TB decreased by 54% and mortality because of TB decreased by 72% in the country in 2015,[@R4] 4000 deaths among HIV-infected individuals and 26 000 deaths among HIV-negative individuals still occurred in 2016.[@R3] The decline in the incidence and mortality could in part be attributed to improvement in the TB detection rate,[@R4] provision of isoniazid preventive therapy for HIV-infected individuals[@R5] and early initiation of antiretroviral therapy (ART),[@R6] a community-based package involving health extension workers.[@R7]

Since the discovery of the first anti-TB drug, streptomycin, in 1943[@R8] and the few drugs that followed (isoniazid, rifampicin, ethambutol and pyrazinamide), drug development for drug-susceptible TB has lagged.[@R8] As a result, the same anti-TB drug regimen that was first introduced half a century ago is being used today in the management of active, drug-susceptible TB.[@R10] A 6-month course of four anti-TB drugs is used as a standard treatment for active, drug-susceptible TB disease. Isoniazid and rifampicin serve as the backbone of this regimen, with ethambutol and pyrazinamide given in the first 2 months of treatment.[@R1] However, treatment success could be compromised by poor adherence mainly due to the long treatment period and the development of drug-resistant TB ultimately from the inadequate treatment of active TB.[@R9] In Ethiopia, this four-drug, 6-month and 9--12-month regimen is also recommended as a first-line drug for the treatment of active drug-susceptible pulmonary TB and extrapulmonary TB (EPTB), respectively.[@R12]

Currently, the global TB treatment success rates were 83% for drug-susceptible TB, 78% for HIV-associated TB, 54% for MDR-TB and 30% for extensively drug-resistant TB.[@R3] The WHO Global Plan aimed to achieve three 90-(90)−90 TB control program targets at least by 2025, such as; reach 90% of all people who need TB treatment, including 90% of people in key populations, and achieve at least 90% TB treatment success rate.[@R13]

According to the WHO report, Ethiopia is among the four countries where treatment outcomes of more than 10% of TB cases were not evaluated and documented.[@R3] Even though there has been a recent systematic review on TB treatment outcome in Ethiopia,[@R14] it doesn't clearly assess the overall drug-susceptible TB treatment outcome independently and it also emphasis only on limited factors which associated with TB treatment outcome. In addition to this, there have also been several single studies published on TB treatment outcome in Ethiopia. However, there is a paucity of evidence regarding the overall drug-susceptible TB treatment success at the country level. Therefore, we aimed to get stronger evidence from the available literature regarding drug-susceptible TB treatment success and to identify all potential factors reported that are associated with poor TB treatment outcome in Ethiopia.

Materials and methods {#s2}
=====================

Study design and search strategies {#s2a}
----------------------------------

A systematic review and meta-analysis of published observational studies was conducted. Original studies providing information on the treatment outcomes of patients with TB were identified through a computerised systematic search using PubMed, Google Scholar and Science Direct databases. A combination of keywords and phrases like: 'tuberculosis OR TB', 'treatment OR management', 'Anti-TB', 'outcomes', 'treatment success', 'smear-positive', 'smear-negative', 'Extra-pulmonary-TB' and 'Ethiopia' were used to search articles in the databases (online [supplementary file 1](#SP1){ref-type="supplementary-material"}). The literature search, review and data extraction were performed from February to September 2017. Articles were retrieved up to 15 March 2017. Only those articles written in English language and conducted in Ethiopia were considered for this review.
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Inclusion criteria {#s2b}
------------------

Observational studies fulfilling the following criteria were included in this study: studies reported as original articles; studies done on TB treatment outcomes; studies conducted in Ethiopia and written in English. References from the selected studies were also cross-checked to confirm that no relevant studies were excluded. Outcomes were reported according to the WHO definition of treatment success (cure or treatment completion), failure, default and death.[@R15]

Exclusion criteria {#s2c}
------------------

The following articles were excluded from this review: studies that focus on treatment outcome of patients with MDR-TB; studies that focus on both MDR-TB cases and drug-susceptible TB cases together; studies where full articles were no longer accessed and studies done outside Ethiopia. The selection of articles for review was done in three stages: looking at the titles alone, then abstracts and then the full text ([figure 1](#F1){ref-type="fig"}).

![Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram showing the selection of studies for a systematic review on tuberculosis treatment success in Ethiopia, 2017. MDR, multidrug resistant; TB, tuberculosis.](bmjopen-2018-022111f01){#F1}

Definitions of TB treatment outcomes {#s2d}
------------------------------------

To classify treatment outcomes of patients with TB, the WHO and National Tuberculosis and Leprosy Control Programme (NTLCP) guidelines\' standard definitions were used[@R15] ([table 1](#T1){ref-type="table"}).

###### 

Tuberculosis (TB) treatment outcomes according to WHO and National Tuberculosis and Leprosy Control Programme (NTLCP) guidelines

  Outcome               Definition
  --------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cured                 A patient with TB with bacteriologically confirmed TB at the beginning of treatment who was smear-negative or culture-negative in the last month of treatment and on at least one previous occasion.
  Treatment completed   A patient with TB who completed treatment without evidence of failure, but with no record to show that sputum smear or culture results in the last month of treatment and on at least one previous occasion were negative, either because the tests were not done or because results are unavailable.
  Treatment failed      A patient with TB whose sputum smear or culture is positive at month 5later during treatment.
  Died                  A patient with TB who dies for any reason before starting or during the course of treatment.
  Defaulter             A patient who has been on treatment for at least 4 weeks and whose treatment was interrupted for eight or more consecutive weeks.
  Not evaluated         A patient with TB for whom no treatment outcome is assigned. This includes cases 'transferred out' to another treatment unit as well as cases for whom the treatment outcome is unknown to the reporting unit.
  Treatment success     The sum of cured and treatment completed.

Data extraction and review process {#s2e}
----------------------------------

All of the research articles that were identified from searches of the electronic databases were imported into the ENDNOTE software V.X5 (ThomsonThomson Reuters, USA) and duplicates were removed. Before data extraction had begun, full-length articles of the selected studies were read to confirm the fulfilment of the inclusion criteria. Then, data extraction was performed by three authors (MAS, MBA and EAM) independently. The selected studies were reviewed to extract data like: year of publication; author(s); study design; sample size; type of TB (smear-negative pulmonary TB (PTB^−^), smear-positive pulmonary TB (PTB^+^) and EPTB); HIV status; TB treatment outcomes; geographical location of the study area, and factors affecting TB-treatment outcome (p value of \<0.05). When there was a disagreement in data extraction between the reviewers, it was resolved through discussion and mutual agreement between the investigators.

Methodological quality assessment {#s2f}
---------------------------------

All reviewers (MAS, MBA, EAM, EAG and TMA) independently assessed the methodological quality of included studies by using the Newcastle-Ottawa Scale (NOS).[@R17] The studies which have at least five NOS criteria were considered to be high-quality studies (online [supplementary file 2](#SP2){ref-type="supplementary-material"}).
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Statistical analysis and heterogeneity {#s2g}
--------------------------------------

Statistical analyses were carried out by using Stata V.14 (Stata Corp, College Station, Texas, USA) software[@R19] to estimate the pooled treatment success rate. Statistical heterogeneity between studies was evaluated using Cochran's Q test and the I^2^ statistic.[@R20] Random-effects meta-analyses were used to combine the results of included studies, and was measured as proportions of treatment outcomes with 95% CIs. The detailed description of the original studies was presented in a table and forest plot.

Patient and public involvement {#s2h}
------------------------------

This is a systematic review and meta-analysis, there were no direct involvement of patients and/or the public in this study.

Ethical consideration {#s2i}
---------------------

This study was carried out in strict accordance with the recommendations in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[@R21] Since it is a systematic review and meta-analysis, ethics committee or institutional review board permission was not sought.

Results {#s3}
=======

Literature search results {#s3a}
-------------------------

An electronic search gave a total of 230 articles. Among these 70 were found to be duplicated. Then the titles of 160 articles were checked and 121 were found irrelevant. Five articles were excluded after checking their abstracts. Finally, 34 articles were selected for inclusion in the meta-analysis ([figure 1](#F1){ref-type="fig"}).

Study characteristics {#s3b}
---------------------

This analysis included studies conducted in different regions of the country published from 2005 to 2017. From a total of 230 articles obtained through electronic search, 34 were found to be eligible and were included in this review. Majority 21 (62%) of the included studies were cross-sectional in nature,[@R22] while 12 (35%) of the studies were cohort studies,[@R43] and 1 was a case-control study.[@R55] Most of the studies relied on 5 years data (range of 1--15 years) ([table 2](#T2){ref-type="table"}).

###### 

Characteristics of included studies

  Authors                           Year of publication   Study design                   Duration in years   Study area            Sample size   HIV (%)
  --------------------------------- --------------------- ------------------------------ ------------------- --------------------- ------------- ---------
  Ali *et al* [@R22]                2016                  Cross-sectional study          1                   Addis Ababa           575           29.4
  Amante *et al* [@R55]             2015                  Case-control study             5                   Oromia                976           18.3
  Asebe *et al* [@R44]              2015                  Retrospective cohort study     2.5                 SNNPR                 1156          24.2
  Asres *et al* [@R23]              2016                  Cross-sectional study          7                   SNNPR                 846           9.1
  Balcha T *et al* [@R52]           2015                  Cohort study                   3                   Oromia                439           100
  Belayneh *et al* [@R45]           2016                  Retrospective cohort           5                   Amhara                403           38.5
  Belayneh *et al* [@R24]           2015                  Cross-sectional study          2.7                 Tigray                342           100
  Berhe *et al* [@R25]              2012                  Cross-sectional study          3                   Tigray                407           8.6
  Birlie *et al* [@R46]             2015                  Retrospective cohort study     5                   North-East Ethiopia   810           17.4
  Dangisso *et al* [@R26]           2014                  Retrospective trend analysis   10                  Southern Ethiopia     37 070        --
  Ejeta *et al* [@R47]              2015                  Retrospective cohort study     5                   Western Ethiopia      1175          17.1
  Endris *et al* [@R27]             2014                  Cross-sectional study          5                   Amhara                417           5.8
  Gebreegziabher S *et al* [@R43]   2016                  Prospective cohort             1.7                 Amhara                706           11.6
  Gebremariam *et al* [@R48]        2016                  Retrospective cohort study     6                   Oromia                1649          9.5
  Gebrezgabiher *et al* [@R28]      2016                  Cross-sectional study          5.4                 SNNPR                 1537          --
  Getahun *et al* [@R49]            2013                  Retrospective cohort study     5                   Addis Ababa           6450          --
  Hailu *et al* [@R29]              2014                  Cross-sectional study          5                   Addis Ababa           2708          12.0
  Hamusse *et al* [@R50]            2014                  Retrospective cohort study     15                  Central Ethiopia      14 221        2.0
  Ketema *et al* [@R51]             2014                  Retrospective cohort study     3                   Oromia                2226          9.7
  Mekonnen *et al* [@R30]           2016                  Cross-sectional study          4                   Amhara                949           23.9
  Melese *et al* [@R31]             2016                  Cross-sectional study          5                   Amhara                339           12.7
  Moges *et al* [@R32]              2015                  Cross-sectional study          5                   Amhara                181           --
  Mokenen D. *et al* [@R33]         2015                  Cross-sectional study          4                   Amhara                990           23.8
  Munoz-Sellart *et al* [@R34]      2009                  Cross-sectional study          5                   SNNPR                 851           --
  Munoz-Sellart *et al* [@R35]      2010                  Retrospective audit            5.8                 SNNPR                 6547          --
  Shargie *et al* [@R36]            2005                  Retrospective trend analysis   7                   SNNPR                 19 971        --
  Sinshaw *et al* [@R37]            2017                  Cross-sectional study          5.5                 Amhara                308           100
  Tefera *et al* [@R38]             2016                  Cross-sectional study          5                   Amhara                1280          20.5
  Tesfahuneygn *et al* [@R39]       2015                  Cross-sectional study          5.5                 North-East Ethiopia   4275          13.7
  Tessema *et al* [@R40]            2009                  Cross-sectional study          5                   Amhara                4000          --
  Tilahun *et al* [@R53]            2016                  Retrospective cohort study     5                   Addis Ababa           491           16.7
  Workneh *et al* [@R54]            2016                  Prospective cohort study       1.6                 Amhara                1314          19.9
  Zenebe T *et al* [@R42]           2016                  Cross-sectional study          2                   Afar                  380           47.6
  Zenebe Y *et al* [@R41]           2016                  Cross-sectional study          5                   Amhara                1761          3.5

SNNPR, Southern Nations, Nationalities, and Peoples' Region.

Clinical characteristics of patients {#s3c}
------------------------------------

A total of 117 750 patients with TB were included in the 34 studies. Of these, 51% (59916) patients with TB had PTB^+^, 21% (24428) had PTB^−^ and 17.3% (20400) had EPTB. In this review around 5357 patients had TB-HIV co-infection which is reported by 26 studies. The remaining studies did not provide evidence for TB-HIV co-infection. The detailed description of individual study characteristics is mentioned in [table 2](#T2){ref-type="table"}.

TB treatment outcome in Ethiopia {#s3d}
--------------------------------

This review showed that TB treatment success rate varies from 51% to 95%. [Table 3](#T3){ref-type="table"} shows the detailed description of cure, treatment completed, defaulted, treatment failure, died and transferred out from individual included studies ([table 3](#T3){ref-type="table"}).

###### 

Description of overall treatment outcome of included studies

  Study Id   Authors                          Successful treatment outcome   Unsuccessful treatment outcome   Successful treatment outcome (%)   Cured    Treatment completed   Defaulted   Treatment failure   Died   Transferred out
  ---------- -------------------------------- ------------------------------ -------------------------------- ---------------------------------- -------- --------------------- ----------- ------------------- ------ -----------------
  1\.        Ali *et al* [@R22]               526                            49                               91.5                               106      420                   15          7                   27     0
  2\.        Amante *et al* [@R55]            646                            330                              66.2                               NR       NR                    100         18                  212    0
  3\.        Asebe *et al* [@R44]             814                            144                              85                                 262      552                   97          4                   43     198
  4\.        Asres *et al* [@R23]             695                            88                               88.8                               162      533                   41          1                   46     0
  5\.        Balcha T *et al* [@R52]          349                            59                               85.5                               NR       NR                    32          0                   27     31
  6\.        Belayneh *et al* [@R45]          318                            29                               91.6                               76       242                   7           2                   20     56
  7\.        Belayneh *et al* [@R24]          242                            100                              70.7                               43       199                   7           5                   88     0
  8\.        Berhe *et al* [@R25]             361                            44                               89.1                               343      18                    13          15                  16     6
  9\.        Birlie *et al* [@R46]            685                            68                               91                                 103      582                   2           6                   60     57
  10\.       Dangisso *et al* [@R26]          30 300                         4552                             87                                 14 147   16 153                3263        92                  1197   2087
  11\.       Ejeta *et al* [@R47]             832                            181                              82                                 170      662                   84          2                   95     162
  12\.       Endris *et al* [@R27]            379                            21                               94.8                               77       302                   5           2                   14     17
  13\.       Gebregziabher S *et al* [@R43]   656                            49                               93                                 310      346                   11          10                  28     0
  14\.       Gebremariam *et al* [@R48]       1437                           94                               93.9                               421      1016                  28          7                   59     115
  15\.       Gebrezgabher *et al* [@R28]      1310                           227                              85.2                               181      1129                  171         4                   52     0
  16\.       Getahun *et al* [@R49]           5331                           590                              90                                 1167     4164                  328         26                  236    351
  17\.       Hailu *et al* [@R29]             2193                           188                              92.1                               169      2024                  99          6                   83     184
  18\.       Hamusse *et al* [@R50]           11 888                         2333                             83.6                               9608     2280                  1215        70                  1048   0
  19\.       Ketema *et al* [@R51]            2043                           114                              94.7                               1906     137                   27          24                  63     69
  20\.       Mekonnen *et al* [@R30]          853                            96                               89.9                               132      721                   28          21                  47     0
  21\.       Melese *et al* [@R31]            264                            39                               87.1                               67       197                   8           12                  19     36
  22\.       Moges *et al* [@R32]             127                            13                               90.7                               36       91                    9           3                   1      41
  23\.       Mokenen D *et al* [@R33]         853                            107                              88.9                               NR       NR                    NR          NR                  NR     30
  24\.       Munoz-Sellart *et al* [@R34]     655                            139                              82.5                               NR       NR                    NR          NR                  49     57
  25\.       Munoz-Sellart *et al* [@R35]     4900                           1095                             81.7                               NR       NR                    667         24                  404    552
  26\.       Shargie *et al* [@R36]           8268                           3708                             69                                 NR       NR                    3152        110                 446    2000
  27\.       Sinshaw *et al* [@R37]           238                            70                               77.3                               32       206                   37          2                   31     0
  28\.       Tefera *et al* [@R38]            1016                           129                              88.7                               203      813                   23          4                   102    135
  29\.       Tesfahuneygn *et al* [@R39]      3853                           215                              94.7                               491      3362                  76          13                  126    207
  30\.       Tessema *et al* [@R40]           1181                           1139                             50.9                               NR       NR                    730         6                   403    1680
  31\.       Tilahun *et al* [@R53]           420                            14                               96.8                               NR       NR                    3           2                   9      55
  32\.       Workneh *et al* [@R54]           1228                           86                               93.5                               317      911                   14          15                  57     0
  33\.       Zenebe T *et al* [@R42]          320                            52                               86                                 128      192                   34          1                   17     8
  34\.       Zenebe Y *et al* [@R41]          542                            129                              80.8                               NR       NR                    30          1                   98     1090

NR, not reported.

Meta-analysis {#s3e}
-------------

The Funnel plot depicted in [figure 2](#F2){ref-type="fig"} showed that there is symmetry between the studies and no significant publication bias was seen, or small study effect was insignificant. The sensitivity analysis also showed the absence of an excessive influence of individual studies. The point estimates calculated after omission of each study one by one lies within the CI of the 'combined' analysis (online [supplementary file 3](#SP3){ref-type="supplementary-material"}) ([figure 2](#F2){ref-type="fig"}).
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![Funnel plot of SE by logit event rate.](bmjopen-2018-022111f02){#F2}

The overall estimate of TB treatment success {#s3f}
--------------------------------------------

As indicated in the following forest plot the overall drug-susceptible TB treatment success rate in Ethiopia is 86% (95 % CI 83% to 88%) ([figure 3](#F3){ref-type="fig"}). Subgroup analysis based on the study area showed that Addis Ababa (93%), Oromia (84%), Amhara (86%), SNNPR (83%), Tigray (85%) and Afar (86%) had TB treatment success rate ([figure 4](#F4){ref-type="fig"}). The finding of this study also showed that TB treatment outcome in Ethiopia was improving over time. The subgroup analysis showed that TB treatment success from 2005 to 2010 was 71%, from 2011 to 2015 it was 87% and from 2016 to 2017 it was 89% ([figure 5](#F5){ref-type="fig"}).

![Main meta-analysis of success of tuberculosis treatment in Ethiopia.](bmjopen-2018-022111f03){#F3}

![Subgroup analysis of success of tuberculosis treatment in the different regions of Ethiopia.](bmjopen-2018-022111f04){#F4}

![Subgroup analysis of success of tuberculosis treatment based on year of publication.](bmjopen-2018-022111f05){#F5}

Factors significantly associated with poor treatment outcome {#s3g}
------------------------------------------------------------

As indicated in [table 4](#T4){ref-type="table"}, different demographic and clinical characteristics were reported by the reviewed studies as having a significant association with poor TB treatment outcome (p \<0.05). Among these the most frequently mentioned were old age, HIV co-infection, retreatment case and rural residence.

###### 

Factors which had a significant association with poor tuberculosis treatment outcome

  Authors                         Reported factors
  ------------------------------- --------------------------------------------------------------------------------------------------------------------------
  Ali *et al* [@R22]              Age \>65 years, PTB^+^
  Amante *et al* [@R55]           Lack of person to be contacted at a time of treatment interruption, sputum smear-negative diagnosis, HIV-positive status
  Asebe *et al* [@R44]            The age group 45--64 years had significantly lower treatment success rate
  Asres *et al* [@R23]            Older, rural dwellers and HIV-positive
  Balcha T *et al* [@R52]         Low mean upper arm circumference (MUAC)
  Belayneh *et al* [@R45]         NR
  Belayneh *et al* [@R24]         Having low baseline CD4 count (less than 200 cells/L), to be at WHO stage IV
  Berhe *et al* [@R25]            Older age, family sizes greater than five persons, unemployed and retreatment cases
  Birlie *et al* [@R46]           Old age, of low baseline body weight and in TB/HIV co-infected patients
  Dangisso *et al* [@R26]         PTB^−^ cases, older than 65 years, retreatment cases
  Ejeta *et al* [@R47]            HIV serostatus, smear result follow-up at the second, fifth and seventh months
  Endris *et al* [@R27]           No significantly associated factors
  Gebreegziabher *et al* [@R43]   HIV-positive
  Gebremariam *et al* [@R48]      Patients without known HIV status, HIV-positive patients with TB
  Gebrezgabiher *et al* [@R28]    PTB^−^, rural residence, EPTB, 55--64 years old
  Getahun *et al* [@R49]          NR
  Hailu *et al* [@R29]            PTB^+^, HIV co-infection and unknown HIV serostatus
  Hamusse *et al* [@R50]          Patients aged 25--49 years, ≥50 years, retreatment cases and TB/HIV co-infection
  Ketema *et al* [@R51]           HIV-positive patients who remained sputum smear-positive at the end of month 2 and patients who reported missed doses
  Mekonnen *et al* [@R30]         PTB^+^, HIV-positive
  Melese *et al* [@R31]           Female, rural resident, negative smear result at the second month of treatment
  Moges *et al* [@R32]            NR
  Mokenen D. *et al* [@R33]       NR
  Munoz-Sellart *et al* [@R34]    Age \<5 years, living in a rural area, lack of smear conversion in the second month
  Munoz-Sellart *et al* [@R35]    Having a positive smear at the second month of follow-up, PTB^−^, age \>55 years, and being male
  Shargie *et al* [@R36]          Patients on LCC (long-course chemotherapy)
  Sinshaw *et al* [@R37]          Rural residence, baseline weight\<43.7 kg, bedridden functional status, treatment side effect.
  Tefera *et al* [@R38]           NR
  Tesfahuneygn *et al* [@R39]     Non-adherence to anti-TB drugs
  Tessema *et al* [@R40]          Rural areas, age group 25--34 years, PTB^−^
  Tilahun *et al* [@R53]          TB/HIV co-infected patients, age less than 1 years
  Workneh *et al* [@R54]          HIV-positive, diabetes
  Zenebe T *et al* [@R42]         Age, sex, HIV status, associated with treatment outcome
  Zenebe Y *et al* [@R41]         HIV-TB co-infection, young age (15--24 years), rural residence and retreatment of patients

All the factors included in this table had a p value \<0.05 in each study report.

EPTB, extrapulmonary tuberculosis; NR, not reported; PTB, pulmonary tuberculosis; PTB^+^, smear-positive PTB; PTB^−^, smear-negative PTB.

Discussion {#s4}
==========

TB treatment outcome is one of the performance indicators of the effectiveness of TB control programmes.[@R40] This systematic review and meta-analysis was conducted mainly to estimate the pooled treatment success rate of patients with drug-susceptible TB in Ethiopia. This review identified 34 studies (from 2005 to 2017) that assessed the treatment outcomes of drug-susceptible TB. All the studies included were observational studies which were conducted in different regions of Ethiopia; Amhara, Addis Ababa, Tigray, Oromia, Afar and Southern Nations, Nationalities and Peoples' Region (SNNPR). The inclusion of studies conducted in various parts of Ethiopia makes this review representative to figure out the overall TB treatment success rate in the country. We analysed data from these studies which reported on treatment outcomes for a total of 117 750 patients with TB. All the included studies used NTLCP guidelines to define TB treatment outcomes which were adopted from WHO.[@R15]

The result of this study showed that the pooled estimate of TB treatment success rate of drug-susceptible TB in Ethiopia is 86% (95% CI 83% to 88%). This pooled TB treatment success rate was lower than the Ethiopian National Strategic Plan (2010--2015) treatment success target of 90%[@R56] and WHO 2030 international target of ≥90%.[@R3] This study result is relatively higher compared with a recent review done in Ethiopia which was 83.7%.[@R14] According to the 2017 WHO global TB report, Ethiopia achieved a TB treatment success rate of only 84% for new TB cases when compared with the high TB burden countries reached or exceeded a 90% treatment success rate such as; Cambodia (94%), China (94%), Pakistan (93%), Bangladesh (93%), Vietnam (92%), Philippines (91%) and Korea (90%).[@R3] Even though the treatment success rate was below the target, this systematic review and meta-analysis result was good compared with the WHO report. This might be a clue indicating that Ethiopia is within the track of WHO treatment success target currently. However, a collaborative effort among healthcare providers and policy makers is crucial for achieving both national and international treatment targets.

The success rate of TB treatment in the different regions of Ethiopia was also evaluated in this study. Pooled estimate results showed that the lowest treatment success rate of 83% (95% CI 76% to 89%) was in the SNNPR region of Ethiopia[@R23] and the highest success rate was in Addis Ababa (capital city of Ethiopia), that is, 93% (95% CI 90% to 95%).[@R22]This might be due to the differences in the quality of healthcare facilities, the health-seeking behaviour/awareness/of the population towards TB in each region, the emphasis given by regional governments and policy makers towards TB control programmes, and so on.[@R57] Therefore, close supervision of each TB control programme is required to achieve effective nationwide TB control.

There are so many challenges stated as factors that affect TB treatment outcomes.[@R57] The results of this review showed that different demographic and clinical characteristics were reported to have significant association with poor TB treatment outcome in Ethiopia.[@R22] Mainly old age, HIV co-infection, retreatment cases and rural residence were most frequently identified factors associated with poor outcome of TB treatment. In the current study around 5357 patients with TB were HIV-positive. Being HIV-positive lowered the chances of successful treatment outcome. Globally, the treatment success rate of HIV-positive new and relapse TB cases was 78%[@R3] and HIV significantly affects the overall TB treatment success rate which is reported by other similar studies done in Ethiopia, Somalia, Uzbekistan and Turkey.[@R14] Furthermore similar studies done in Ethiopia, Finland and South Korea also reported that older age and retreatment[@R14] were significantly associated with poor TB treatment outcome.[@R57]

In spite of such imperative findings, this study is not without limitations; all the included studies were observational studies; there were differences in the study design among the studies; and studies included were limited to Addis Ababa, Amhara, Oromia, SNNPR, Tigray and Afar. Therefore, interpretation of the results of this review should take into consideration of these limitations.

Conclusion {#s5}
==========

This systematic review and meta-analysis revealed that the success rate of drug-susceptible TB treatment in Ethiopia is below the WHO global target (90%) and there is also a discrepancy in TB treatment success rate among different regions of Ethiopia. In addition to these, HIV co-infection, older age, retreatment cases and rural residence were factors reported most frequently that had a significant association with poor outcome of TB treatment. The overall TB treatment success rate obtained in this study, which is closer to the WHO target, is an indicator of the good efforts in the country initiated against TB. In order to further improve the success rate of TB treatment, it is necessary to make a strategic plan for improving the treatment outcome in patients with TB with HIV co-infection, older patients, patients residing in rural areas and retreatment cases. Special consideration should also be given to regions that had a lower TB treatment success rate.
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